HC Wainwright Reiterates Buy Rating for Beam Therapeutics (NASDAQ:BEAM)

HC Wainwright restated their buy rating on shares of Beam Therapeutics (NASDAQ:BEAM) in a report released on Monday morning,Benzinga reports. They currently have a $80.00 price objective on the stock. HC Wainwright also issued estimates for Beam Therapeutics’ Q1 2026 earnings at ($0.83) EPS, Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.81) EPS, FY2026 earnings at ($3.30) EPS, FY2027 earnings at ($3.00) EPS, FY2028 earnings at ($1.91) EPS and FY2029 earnings at ($1.44) EPS.

Several other research firms have also weighed in on BEAM. Cantor Fitzgerald raised Beam Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Wednesday, January 29th. Sanford C. Bernstein raised shares of Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 7th. Scotiabank assumed coverage on shares of Beam Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $24.00 price objective for the company. Royal Bank of Canada cut their price objective on Beam Therapeutics from $27.00 to $24.00 and set a “sector perform” rating for the company in a research report on Wednesday, November 6th. Finally, Wedbush reaffirmed an “outperform” rating and set a $57.00 price objective on shares of Beam Therapeutics in a research report on Monday, January 13th. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Beam Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $47.67.

Beam Therapeutics Stock Up 8.0 %

BEAM stock opened at $27.82 on Monday. The company has a market capitalization of $2.30 billion, a P/E ratio of -15.81 and a beta of 1.92. The company has a 50-day simple moving average of $26.49 and a 200 day simple moving average of $25.77. Beam Therapeutics has a fifty-two week low of $20.84 and a fifty-two week high of $49.50.

Beam Therapeutics (NASDAQ:BEAM) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.01). The firm had revenue of $14.30 million for the quarter, compared to the consensus estimate of $14.52 million. Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The business’s revenue for the quarter was down 16.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.22) earnings per share. Equities analysts anticipate that Beam Therapeutics will post -4.57 EPS for the current year.

Insider Activity

In other news, insider Christine Bellon sold 1,241 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $24.68, for a total value of $30,627.88. Following the completion of the transaction, the insider now owns 102,968 shares of the company’s stock, valued at $2,541,250.24. The trade was a 1.19 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO John M. Evans sold 30,000 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $26.75, for a total value of $802,500.00. Following the sale, the chief executive officer now directly owns 908,659 shares in the company, valued at $24,306,628.25. The trade was a 3.20 % decrease in their position. The disclosure for this sale can be found here. 4.20% of the stock is currently owned by company insiders.

Institutional Trading of Beam Therapeutics

A number of large investors have recently bought and sold shares of BEAM. Charles Schwab Investment Management Inc. boosted its holdings in shares of Beam Therapeutics by 6.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 629,492 shares of the company’s stock valued at $15,423,000 after buying an additional 36,226 shares during the period. Bellevue Group AG lifted its position in Beam Therapeutics by 7.1% in the 3rd quarter. Bellevue Group AG now owns 1,518,121 shares of the company’s stock valued at $37,194,000 after acquiring an additional 100,000 shares in the last quarter. Geode Capital Management LLC boosted its stake in Beam Therapeutics by 4.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,807,683 shares of the company’s stock worth $44,297,000 after purchasing an additional 78,102 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its holdings in Beam Therapeutics by 59.7% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,552,829 shares of the company’s stock worth $87,044,000 after purchasing an additional 1,328,414 shares in the last quarter. Finally, Algert Global LLC raised its stake in shares of Beam Therapeutics by 282.0% in the 3rd quarter. Algert Global LLC now owns 43,523 shares of the company’s stock valued at $1,066,000 after purchasing an additional 32,130 shares during the period. 99.68% of the stock is owned by institutional investors.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.